Bottle Label 25 mg (71610 0224 30)
Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-224
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
This is a comparison between two medications, Atenolol and Losartan Potassium, showing a 13% reduction in the risk of primary endpoint (not specified what that is) in patients taking Losartan Potassium. The study's duration was 66 months and was carried out in monthly intervals, with data recorded at each interval.*
Figure 2 (Spl Image3 Figure2)
This text presents information regarding medication substitution. Atenolol can be replaced by Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001. Additionally, there is a table showing the percentage of patients with fatal/non-fatal strokes over time intervals ranging from 6 to 66 months.*
Figure 3 (Spl Image4 Figure3)
The text describes demographic subgroup analysis for primary endpoint events in patients taking either Losartan Potassium or Atenolol. The primary composite stroke events were analyzed across different subgroups such as age, gender, race, diabetes, and history of CVD. The results of the analysis are presented in tabular form, along with Hazard Ratios (95%CI) and event rates for each subgroup. The table also includes a legend to interpret the symbols used in the table, and a note that the analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 (Spl Image5 Figure4)
This is a graph showing the percentage of patients who experienced an event over a course of 48 months while taking either Losartan Potassium or a placebo medication. The risk reduction with Losartan Potassium compared to placebo is 16.1%, which was found to be statistically significant with a p-value of 0.022.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
